REGN
Price
$549.06
Change
-$21.53 (-3.77%)
Updated
Jul 15, 04:06 PM (EDT)
Capitalization
61.6B
17 days until earnings call
VRTX
Price
$464.62
Change
-$7.74 (-1.64%)
Updated
Jul 15, 03:17 PM (EDT)
Capitalization
121.3B
20 days until earnings call
Interact to see
Advertisement

REGN vs VRTX

Header iconREGN vs VRTX Comparison
Open Charts REGN vs VRTXBanner chart's image
Regeneron Pharmaceuticals
Price$549.06
Change-$21.53 (-3.77%)
Volume$100
Capitalization61.6B
Vertex Pharmaceuticals
Price$464.62
Change-$7.74 (-1.64%)
Volume$818
Capitalization121.3B
REGN vs VRTX Comparison Chart in %
Loading...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REGN vs. VRTX commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a StrongBuy and VRTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (REGN: $570.59 vs. VRTX: $472.35)
Brand notoriety: REGN: Notable vs. VRTX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 56% vs. VRTX: 51%
Market capitalization -- REGN: $61.6B vs. VRTX: $121.3B
REGN [@Biotechnology] is valued at $61.6B. VRTX’s [@Biotechnology] market capitalization is $121.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $305.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 2 green FA rating(s).

  • REGN’s FA Score: 1 green, 4 red.
  • VRTX’s FA Score: 2 green, 3 red.
According to our system of comparison, VRTX is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 6 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).

  • REGN’s TA Score: 6 bullish, 4 bearish.
  • VRTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, REGN is a better buy in the short-term than VRTX.

Price Growth

REGN (@Biotechnology) experienced а +6.04% price change this week, while VRTX (@Biotechnology) price change was +2.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.65%. For the same industry, the average monthly price growth was +18.33%, and the average quarterly price growth was +31.96%.

Reported Earning Dates

REGN is expected to report earnings on Oct 30, 2025.

VRTX is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+2.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($121B) has a higher market cap than REGN($61.6B). VRTX has higher P/E ratio than REGN: VRTX (32.76) vs REGN (14.50). VRTX YTD gains are higher at: 17.296 vs. REGN (-19.677). REGN has higher annual earnings (EBITDA): 5.53B vs. VRTX (-74.9M). REGN has more cash in the bank: 8.35B vs. VRTX (6.2B). VRTX has less debt than REGN: VRTX (1.65B) vs REGN (2.71B). REGN has higher revenues than VRTX: REGN (14.1B) vs VRTX (11.1B).
REGNVRTXREGN / VRTX
Capitalization61.6B121B51%
EBITDA5.53B-74.9M-7,381%
Gain YTD-19.67717.296-114%
P/E Ratio14.5032.7644%
Revenue14.1B11.1B127%
Total Cash8.35B6.2B135%
Total Debt2.71B1.65B164%
FUNDAMENTALS RATINGS
REGN vs VRTX: Fundamental Ratings
REGN
VRTX
OUTLOOK RATING
1..100
2312
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10026
SMR RATING
1..100
5391
PRICE GROWTH RATING
1..100
6255
P/E GROWTH RATING
1..100
9631
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (4) in the Biotechnology industry is significantly better than the same rating for VRTX (77). This means that REGN’s stock grew significantly faster than VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (26) in the Biotechnology industry is significantly better than the same rating for REGN (100). This means that VRTX’s stock grew significantly faster than REGN’s over the last 12 months.

REGN's SMR Rating (53) in the Biotechnology industry is somewhat better than the same rating for VRTX (91). This means that REGN’s stock grew somewhat faster than VRTX’s over the last 12 months.

VRTX's Price Growth Rating (55) in the Biotechnology industry is in the same range as REGN (62). This means that VRTX’s stock grew similarly to REGN’s over the last 12 months.

VRTX's P/E Growth Rating (31) in the Biotechnology industry is somewhat better than the same rating for REGN (96). This means that VRTX’s stock grew somewhat faster than REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNVRTX
RSI
ODDS (%)
Bearish Trend 2 days ago
41%
Bearish Trend 2 days ago
61%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
59%
MACD
ODDS (%)
Bullish Trend 2 days ago
61%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 6 days ago
59%
Declines
ODDS (%)
Bearish Trend 9 days ago
56%
Bearish Trend 19 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
54%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EUO28.120.18
+0.64%
ProShares UltraShort Euro
FLXR39.320.03
+0.08%
TCW Flexible Income ETF
OACP22.62-0.01
-0.04%
OneAscent Core Plus Bond ETF
ETHE24.85-0.07
-0.28%
Grayscale Ethereum Trust ETF
NVDX15.59-0.17
-1.05%
T-REX 2X Long NVIDIA Daily Target ETF